MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Часто задаваемые вопросы
В каком секторе работает MaxCyte Inc (MXCT)?
MaxCyte Inc относится к сектору Здравоохранение.
Какова текущая цена акций MaxCyte Inc (MXCT)?
По последним данным, цена акций MaxCyte Inc составляет 1,54 $, предыдущее закрытие — 1,51 $. За последнюю торговую сессию акции MaxCyte Inc выросли на 0,03 $, что соответствует росту на 1,99%.
Выплачивает ли MaxCyte Inc (MXCT) дивиденды?
Нет, MaxCyte Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у MaxCyte Inc (MXCT)?
У компании MaxCyte Inc бета 1.494, что указывает на повышенную волатильность по сравнению с рынком.
